Pentacyclic triterpene derivatives and preparation methods and uses thereof

By designing a pentacyclic triterpene derivative, using amide bond combination compounds, the antioxidant activity is improved, the problem of insufficient activity of existing pentacyclic triterpene compounds is solved, and effective inhibition and anti-inflammatory mediator release is achieved. Effect.

CN118791546BInactive Publication Date: 2024-11-26SOUTH CHINA UNIV OF TECH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411267484.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-11
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing pentacyclic triterpenes have poor activity in inhibiting the release of inflammatory mediators, making it difficult to effectively solve the problem of inflammatory response.

Method used

By designing a pentacyclic triterpene derivative, combining compounds using amide bonds, reducing acidity and significantly improving antioxidant activity through synergistic effects, thereby inhibiting the release of inflammatory mediators and oxidative stress response.

Benefits of technology

It significantly improves anti-inflammatory activity, can effectively inhibit the release of inflammatory mediators, and provides better application prospects for anti-inflammatory drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118791546B_ABST
    Figure CN118791546B_ABST
Patent Text Reader

Abstract

The present application example proposes a pentacyclic triterpene derivative and its preparation method and use. The pentacyclic triterpene derivative provided in the present application example combines two compounds in the form of an amide bond, which not only reduces the acidity of the lead compound, but also significantly improves the antioxidant activity of the compound through synergistic effects, thereby effectively inhibiting the release of inflammatory mediators and oxidative stress reactions during inflammation, and improving the anti-inflammatory activity of the derivative, indicating that the pentacyclic triterpene derivative has good application prospects in the preparation of anti-inflammatory drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of pharmaceutical preparations, and in particular to a pentacyclic triterpene derivative and a preparation method and use thereof. Background Art

[0002] Inflammation is a physiological reaction, usually a non-specific response of tissue to injury, infection or stimulation. The process of inflammation involves a complex interaction of immune cells, blood vessels and molecular signaling pathways, aimed at clearing damaging substances, pathogens or irritants, and promoting tissue repair. Inflammatory factors are a class of protein molecules involved in inflammatory responses, and they play an important role in the body's immune response. Common inflammatory factors include tumor necrosis factor (TNF), interleukin (IL) family members (such as IL-1, IL-6, IL-8, etc.), interferon (IFN), etc. Among them, the abnormal expression of inflammatory factors may cause tissue damage, systemic inflammatory response, immunosuppression and other problems in the body.

[0003] At present, pentacyclic triterpenoid compounds extracted from plants, such as asiatic acid, scutellariae acid and 23-hydroxyursulic acid, have anti-inflammatory activity, and can inhibit the release of TNF-α in the lipopolysaccharide (LPS)-stimulated mouse macrophage RAW 264.7 inflammation model; however, the above compounds have the defect of poor activity.

[0004] In view of this, the development of a compound with high anti-inflammatory activity has become an urgent need. Summary of the invention

[0005] The purpose of the present application is to provide a pentacyclic triterpene derivative and a preparation method and use thereof.

[0006] To achieve the above objectives, the present application proposes the following technical solutions:

[0007] In a first aspect, the present invention provides a pentacyclic triterpene derivative, wherein the pentacyclic triterpene derivative has a compound having a structure shown in Formula I or a pharmaceutically acceptable salt thereof:

[0008] ,

[0009] Wherein, R1, R2, R3, and R4 are each independently selected from hydrogen or hydroxyl, and R1, R2, R3, and R4 are not hydrogen or hydroxyl at the same time; n is an integer of 2 to 4.

[0010] As an implementation mode, n is 2 or 4.

[0011] In a second aspect, the present application provides a method for preparing the pentacyclic triterpene derivatives as described in the first aspect, the preparation method comprising:

[0012] Adding compound 1, a condensing agent and an alkaline reagent into an organic solvent to react and generate compound 2;

[0013] Adding compound 2, diamine and alkaline reagent into an organic solvent to react and generate compound 3;

[0014] Compound 3, compound 2 and an alkaline reagent are added to an organic solvent to react to generate a pentacyclic triterpene derivative;

[0015] The structural formulas of Compound 1, Compound 2 and Compound 3 are as follows:

[0016] , , ;

[0017] R1 and R2 are each independently selected from hydrogen or hydroxyl, and n is an integer of 2 to 4.

[0018] As an embodiment, the condensing agent is O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroboric acid.

[0019] As an embodiment, the alkaline reagent is at least one of triethylamine and N,N-diisopropylethylamine.

[0020] As an embodiment, the organic solvent is one of tetrahydrofuran, N,N-dimethylformamide and dichloromethane.

[0021] As an embodiment, the diamine is one of 1,2-ethylenediamine, 1,3-propylenediamine, and 1,4-butylenediamine.

[0022] In a third aspect, the embodiments of the present application provide the use of the pentacyclic triterpene derivatives as described in the first aspect in the preparation of a drug for preventing, alleviating or treating inflammation.

[0023] Wherein, the drug is a drug used to inhibit the release of inflammatory factors.

[0024] The embodiments of the present application have at least the following beneficial effects:

[0025] The pentacyclic triterpene derivatives provided in the examples of the present application combine two compounds in the form of an amide bond, which not only reduces the acidity of the lead compound, but also significantly improves the antioxidant activity of the compound through a synergistic effect, thereby effectively inhibiting the release of inflammatory mediators and oxidative stress response during inflammation, thereby improving the anti-inflammatory activity of the derivatives, indicating that the pentacyclic triterpene derivatives have good application prospects in the preparation of anti-inflammatory drugs.

[0026] Additional aspects and advantages of the present application will be partially given in the following description, which will become apparent from the following description, or will be understood through the practice of the present application. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 is the hydrogen nuclear magnetic resonance spectrum of compound AA-RA-1 in Example 1;

[0028] Figure 2 is the hydrogen nuclear magnetic resonance spectrum of compound AA-RA-2 in Example 2;

[0029] Figure 3 is the hydrogen nuclear magnetic resonance spectrum of compound AA-UA-1 in Example 3;

[0030] Figure 4 is the hydrogen nuclear magnetic resonance spectrum of compound AA-UA-2 in Example 4;

[0031] Figure 5 is the hydrogen nuclear magnetic resonance spectrum of compound RA-UA-1 in Example 5;

[0032] Figure 6 is the hydrogen nuclear magnetic resonance spectrum of compound RA-UA-2 in Example 6;

[0033] Figure 7 Schematic diagram of the test results of the test compound at a concentration of 20 μM for 24 h on LPS-induced TNF-α secretion in mouse macrophage RAW264.7 cells. DETAILED DESCRIPTION

[0034] The technical solutions in the embodiments will be described clearly and completely below in combination with the embodiments and drawings of the present application. Obviously, the embodiments described below are only part of the embodiments of the present application, rather than all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0035] It should be understood that when used in this specification and the appended claims, the terms "include" and "comprises" indicate the presence of described features, integers, steps, operations, elements and / or components, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components and / or combinations thereof.

[0036] It should also be understood that the terms used in this specification of the embodiments of the present application are only for the purpose of describing specific embodiments and are not intended to limit the embodiments of the present application. As used in the specification of the embodiments of the present application and the appended claims, unless the context clearly indicates otherwise, the singular forms of "a", "an" and "the" are intended to include plural forms.

[0037] Some of the terms and materials involved in this embodiment are explained below to facilitate understanding by those skilled in the art.

[0038] THF: tetrahydrofuran.

[0039] DMF: N,N-dimethylformamide.

[0040] DIPEA: N,N-diisopropylethylamine.

[0041] TBTU: O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate.

[0042] The pentacyclic triterpene derivatives of the present invention and their preparation methods and uses are described in detail below.

[0043] First, the pentacyclic triterpene derivative of this example is described.

[0044] Pentacyclic triterpene derivatives

[0045] Current pentacyclic triterpenoid compounds, such as asiatic acid, scutellariae acid and 23-hydroxyursulic acid, have anti-inflammatory activity and can inhibit the release of TNF-α in the lipopolysaccharide (LPS)-stimulated mouse macrophage RAW 264.7 inflammation model; however, the above compounds have the defect of poor activity.

[0046] In view of this, this embodiment provides a pentacyclic triterpene derivative; specifically, the pentacyclic triterpene derivative has a compound having the structure shown below or a pharmaceutically acceptable salt thereof:

[0047] ;

[0048] Wherein, R1, R2, R3, and R4 are each independently selected from hydrogen or hydroxyl, and R1, R2, R3, and R4 are not hydrogen or hydroxyl at the same time; n is an integer of 2 to 4.

[0049] It can be understood that the pentacyclic triterpene derivative provided in this embodiment is a twin-drug derivative; based on the above structure, the pentacyclic triterpene derivative provided in the embodiment of the present application combines two compounds in the form of an amide bond, which not only reduces the acidity of the lead compound, but also significantly improves the antioxidant activity of the compound through synergistic effects, thereby effectively inhibiting the release of inflammatory mediators and oxidative stress response during inflammation, and improving the anti-inflammatory activity of the derivative, indicating that the pentacyclic triterpene derivative has good application prospects in the preparation of anti-inflammatory drugs.

[0050] As a preferred embodiment, n is 2 or 4.

[0051] The above pentacyclic triterpene derivatives will be further described below with reference to specific examples.

[0052] Exemplarily, R1, R2, R3, R4 and n can be selected from the groups or integers shown in Table 1 below, respectively, and the corresponding compounds are obtained;

[0053] Table 1:

[0054]

[0055] Based on the groups or integers shown in R1, R2, R3, R4 and n in Table 1, the pentacyclic triterpene derivative provided in this embodiment can be selected from at least one of the following compounds or pharmaceutically acceptable salts thereof:

[0056] , , , , , .

[0057] It is to be understood that the pharmaceutically acceptable salts of the compounds described above provided in this embodiment may be sodium salts, potassium salts, ammonium salts, amino acid salts, lactates, hydrochlorides, phosphates, acetates, malates, citrates or aspartates, etc. This embodiment does not specifically limit the pharmaceutical salts.

[0058] Next, the method for producing the above-mentioned pentacyclic triterpene derivative will be described.

[0059] Preparation method

[0060] This embodiment also provides a method for preparing the above pentacyclic triterpene derivatives, which comprises:

[0061] (1) adding compound 1, a condensing agent and an alkaline reagent into an organic solvent to react to generate compound 2;

[0062] (2) adding compound 2, diamine and alkaline reagent into an organic solvent to react to generate compound 3;

[0063] (3) adding compound 3, compound 2 and an alkaline reagent into an organic solvent to react to generate a pentacyclic triterpene derivative;

[0064] The structural formulas of Compound 1, Compound 2 and Compound 3 are as follows:

[0065] , , ;

[0066] R1 and R2 are each independently selected from hydrogen or hydroxyl, and n is an integer of 2 to 4.

[0067] Specifically, the above preparation method can refer to the following synthetic route:

[0068] .

[0069] The various steps of the above-mentioned preparation method will be further described below:

[0070] In step (1), the condensing agent is O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroboric acid; the alkaline reagent is at least one of triethylamine and N,N-diisopropylethylamine; the organic solvent is one of tetrahydrofuran, N,N-dimethylformamide and dichloromethane, preferably tetrahydrofuran;

[0071] As a preferred embodiment, the molar ratio of compound 1 to the condensing agent and the alkaline reagent is 1:1.3:0.5-1; for example: 1:1.3:0.5, 1:1.3:0.6, 1:1.3:0.7, 1:1.3:0.8, 1:1.3:0.9, 1:1.3:1;

[0072] In step (1), compound 1 is used as a lead compound, and O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroboric acid (TBTU) is used as a condensation agent to generate compound 2 (active ester of the lead compound);

[0073] Typically, the reaction time of step (1) is 12-24 hours, for example 12 hours, 14 hours or 24 hours; the reaction temperature is 10-40°C, for example 10°C, 15°C, 20°C, 25°C (or room temperature), 30°C, 35°C, 40°C;

[0074] In step (2), the diamine is one of 1,2-ethylenediamine, 1,3-propylenediamine, and 1,4-butylenediamine; the alkaline reagent is at least one of triethylamine and N,N-diisopropylethylamine; the organic solvent is one of tetrahydrofuran, N,N-dimethylformamide, and dichloromethane, preferably N,N-dimethylformamide;

[0075] In step (2), the compound 2 (active ester) prepared above is reacted with a diamine to generate an amide (i.e., compound 3) with an exposed amine group on one side;

[0076] Typically, the reaction time of step (2) is 12-24 h, for example 12 h, 14 h or 24 h; the reaction temperature is 10-40° C., for example 10° C., 15° C., 20° C., 25° C. (or room temperature), 30° C., 35° C., 40° C.;

[0077] In step (3), based on the active ester of the lead compound (i.e., compound 2) prepared above, compound 3, the active ester of the lead compound (compound 2), and an alkaline reagent are added to an organic solvent to react to generate a pentacyclic triterpene derivative (target compound);

[0078] Illustratively, the lead compound used in this embodiment is one of scutellariae acid, asiaticacid, and 23-hydroxyursulic acid.

[0079] In the above steps, rabic acid (RA), asiatic acid (AA), and 23-hydroxyursulic acid (UA) are used as lead compounds, and O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) is used as a condensation agent to generate active esters of the corresponding compounds (i.e., the active ester of the lead compound, compound 2), and the active ester of the lead compound (compound 2) is reacted with an amide (compound 3) with an exposed amine group on one side, and they are combined in pairs in the form of amide bonds to generate twin-drug pentacyclic triterpene derivatives, which not only reduces the acidity of the lead compound, but also significantly improves the antioxidant activity of the compound through synergistic effects, thereby effectively inhibiting the release of inflammatory mediators and oxidative stress response during inflammation, thereby improving the anti-inflammatory activity of the derivatives.

[0080] Among them, the alkaline reagent used when compound 3 reacts with the active ester of the above-mentioned lead compound (compound 2) is at least one of triethylamine and N,N-diisopropylethylamine, preferably N,N-diisopropylethylamine; the organic solvent used is one of tetrahydrofuran, N,N-dimethylformamide, and dichloromethane, preferably N,N-dimethylformamide.

[0081] It can be understood that the reaction time of compound 3 and the active ester of the above-mentioned lead compound (compound 2) is 12-24h, for example 12h, 14h or 24h; the reaction temperature is 10-40℃, for example 10℃, 15℃, 20℃, 25℃ (or normal temperature), 30℃, 35℃, 40℃.

[0082] In the prior art, due to the large steric hindrance of the C-28 carboxyl group of pentacyclic triterpenoid compounds, the most commonly used method for derivatizing the carboxyl group of pentacyclic triterpenoid compounds is to first protect the exposed hydroxyl group, then make the carboxyl group into a more active acyl chloride and then react with amines. However, the acyl chloride is highly active and difficult to store and derive in large quantities, and requires highly toxic reagents such as oxalyl chloride and pyridine, which is cumbersome and has high environmental and safety costs.

[0083] The preparation method of this embodiment uses a condensation agent to react with a carboxylic acid to generate an active ester, which is then reacted with an amine compound. It can be stably stored at room temperature, which is convenient for subsequent derivatization. That is, the derivatization method of the pentacyclic triterpene derivative in this embodiment has fewer steps and a high yield, and can be stored at room temperature, which is convenient for large-scale derivatization.

[0084] Next, the use of the above-mentioned pentacyclic triterpene derivatives will be explained.

[0085] Uses of pentacyclic triterpene derivatives

[0086] As mentioned above, the pentacyclic triterpene derivative provided in this embodiment connects two compounds through an amide bond to obtain a twin-drug derivative. The synergistic effect of the twin-drug derivative significantly improves the antioxidant activity of the compound, thereby effectively inhibiting the release of inflammatory mediators and oxidative stress response during inflammation, thereby improving the anti-inflammatory activity of the derivative.

[0087] Based on this, the pentacyclic triterpene derivatives provided in this embodiment can be used to prepare drugs for preventing, alleviating or treating inflammation.

[0088] Specifically, the above-mentioned drug is a drug for inhibiting the release (secretion) of inflammatory factors.

[0089] Generally, when the above pentacyclic triterpene derivatives are prepared into corresponding anti-inflammatory drugs, the drugs also include pharmaceutically acceptable carriers and / or adjuvants.

[0090] The drug described in this embodiment uses a pentacyclic triterpene derivative as an active ingredient, and does not exclude changes in the formulation system and administration method, pharmaceutical salts of the pentacyclic triterpene derivatives after simple chemical modification and adjustment, and the combined use of multiple compounds.

[0091] For example, in this embodiment, one or more compounds of the pentacyclic triterpene derivatives of this embodiment can be formulated as active ingredients in a non-toxic, inert and pharmaceutically acceptable carrier and / or adjuvant; the formulated drug can be administered by conventional routes, including but not limited to oral, intramuscular, intraperitoneal, intravenous, subcutaneous, intradermal or topical administration.

[0092] For example, when the dosage form of the drug of this embodiment is a drug for oral administration, it contains a safe and effective amount of pentacyclic triterpene derivatives and a pharmaceutically acceptable carrier and / or adjuvant. The drug for oral administration can be made into tablets, pills, powders, granules, capsules, emulsions, syrups, ointments, suppositories and other common dosage forms; in this embodiment, no specific restrictions are made on the carrier and / or adjuvant, and the carrier and / or adjuvant can be adaptively adjusted according to the specific drug dosage form.

[0093] Generally, the "effective amount" of a compound (pentacyclic triterpene derivative) refers to an amount sufficient to cause a target biological response. As will be appreciated by those of ordinary skill in the art, the effective amount of the compound in this embodiment may vary according to factors such as the vehicle and the age, health, and inflammatory symptoms of the subject.

[0094] Among them, the effective amount includes a therapeutically effective amount and a preventive effective amount.

[0095] Unless otherwise specified, the "therapeutically effective amount" of the compound used in this embodiment is an amount sufficient to provide a benefit in the treatment of inflammation, or an amount that minimizes the improvement or alleviation of one or more symptoms (manifestations) associated with an inflammatory state. The "preventive effective amount" of the compound used in this embodiment is an amount sufficient to prevent inflammation, or an amount sufficient to prevent one or more symptoms associated with an inflammatory state.

[0096] It is understandable that the drug of this embodiment can also be made into an injection. For example, the pentacyclic triterpene derivative can be mixed with water for injection, physiological saline, and glucose water under a sterile operating environment to prepare a corresponding injection (for example, a concentration of 20 μM). The above injection can be prepared by conventional methods.

[0097] The present application will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate / explain the present application and are not used to limit the scope of the present application.

[0098] In the following examples, the materials, reagents and instruments used can be purchased from commercial sources unless otherwise specified.

[0099] Example 1

[0100] The synthesis route of compound AA-RA-1 is as follows:

[0101] .

[0102] Specifically, the steps include:

[0103] Step (1): Synthesis of compound RA-T: In a 100 mL round-bottom flask, RA (0.5023 g, 1.0 mmol) and TBTU (0.4295 g, 1.3 mmol) were added in sequence, followed by THF (10 mL) and N,N-diisopropylethylamine (DIPEA, 270 μL, about 1.5 mmol). The mixture was stirred at room temperature for 12 h. The reaction progress was monitored by TLC. The developing solvent ratio was V: 石油醚 :V 乙酸乙酯 =2:1;

[0104] After treatment, the solvent was first spin-dried, ethyl acetate (30 mL) was added to dissolve, and then washed twice with 1M hydrochloric acid solution (30 mL), washed twice with saturated sodium bicarbonate solution (30 mL), and washed twice with saturated sodium chloride solution (30 mL). The ethyl acetate organic layer was collected and dried over anhydrous sodium sulfate;

[0105] After filtration, the organic layer was collected and ethyl acetate was removed by distillation under reduced pressure, and then purified by column chromatography to obtain a white solid compound RA-T (0.6041 g, 97.5%);

[0106] The structural characterization data of compound RA-T are as follows:

[0107] 1H NMR (400 MHz, CDCl3) δ 8.04 (dd, J = 8.4 Hz, 1H), 7.51 (dd, J =8.2, 7.0 Hz, 1H), 7.43 - 7.32 (m, 2H), 5.40 (t, J = 3.7 Hz, 1H), 3.76 (d, J =10.3 Hz, 1H), 3.65 (dd, J = 8.9, 6.9 Hz, 1H), 3.45 (d, J = 10.3 Hz, 1H), 2.84(td, J = 13.5, 4.3 Hz, 1H), 2.64 (s, 1H), 2.28 (dt, J = 12.9, 3.3 Hz, 1H),2.03 (td, J = 12.8, 12.2, 3.5 Hz, 3H), 1.97 (dd, J = 9.1, 5.2 Hz, 2H), 1.94 -1.80 (m, 3H), 1.66 (d, J = 7.5 Hz, 1H), 1.63 (dd, J = 10.2, 5.7 Hz, 4H), 1.58- 1.42 (m, 5H), 1.41 (d, J = 6.9 Hz, 1H), 1.34 (s, 3H), 1.29 (s, 2H), 1.24(s, 3H), 1.12 (s, 1H), 1.00 (d, J = 6.5 Hz, 3H), 0.95 (s, 3H), 0.91 (s, 3H),0.83 (s, 3H).

[0108] Step (2): Synthesis of compound AA-T: In a 100 mL round-bottom flask, AA (0.5011 g, 1.0 mmol), TBTU (0.4273 g, 1.3 mmol) were added in sequence, followed by THF (10 mL) and DIPEA (270 μL, about 1.5 mmol), and the reaction was stirred at room temperature for 12 h before the reaction was completed. The remaining operations were the same as the synthesis of RA-T to obtain a white solid compound AA-T (0.5924 g, 95.6%);

[0109] The structural characterization data of compound AA-T are as follows:

[0110] 1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 8.4 Hz, 1H), 7.51 (dd, J = 8.2,7.0 Hz, 1H), 7.43 - 7.32 (m, 2H), 5.40 (t, J = 3.7 Hz, 1H), 3.76 (d, J = 10.3Hz, 1H), 3.65 (dd, J = 8.9, 6.9 Hz, 1H), 3.45 (d, J = 10.3 Hz, 1H), 2.84 (td,J = 13.5, 4.3 Hz, 1H), 2.64 (s, 1H), 2.28 (dt, J = 12.9, 3.3 Hz, 1H), 2.03(td, J = 12.8, 12.2, 3.5 Hz, 3H), 1.97 (dd, J = 9.1, 5.2 Hz, 2H), 1.94 - 1.80(m, 3H), 1.66 (d, J = 7.5 Hz, 1H), 1.63 (dd, J = 10.2, 5.7 Hz, 4H), 1.58 -1.42 (m, 5H), 1.41 (d, J = 6.9 Hz, 1H), 1.34 (s, 3H), 1.29 (s, 2H), 1.24 (s,4H), 1.12 (s, 1H), 1.08 - 0.85 (m, 12H), 0.83 (s, 3H).

[0111] Step (3): Synthesis of compound AA-T-1: In a 100 mL round-bottom flask, add 1,2-ethylenediamine (25 μL, 0.38 mmol) and triethylamine (46 μL, 0.33 mmol) to DMF (2 mL) and keep stirring. Dissolve AA-T (0.2003 g, 0.33 mmol) in DMF (2 mL) and slowly add dropwise to the above solution. React at room temperature for 12 h. Monitor the reaction progress by TLC. The developing solvent ratio is V 二氯甲烷 :V 甲醇 =10:1;

[0112] After the reaction is completed, the solvent is first removed by vacuum distillation, then dissolved with n-butanol (20 mL), washed with saturated sodium chloride solution (20 mL) 4-5 times, and the n-butanol phase is dried over anhydrous sodium sulfate. Filter, remove the solvent by vacuum distillation of n-butanol, and then separate the product by column chromatography to obtain a white solid AA-T-1 (0.1129 g, 64.5%);

[0113] Step (4): Synthesis of compound AA-RA-1: In a 100 mL round-bottom flask, add AA-T-1 (0.1109 g, 0.21 mmol) and RA-T (0.1439 g, 0.23 mmol), dissolve in DMF (4 mL), add triethylamine (36 μL, about 0.36 mmol), react at room temperature for 12 h, monitor the reaction progress by TLC, and use a developing solvent ratio of V 二氯甲烷 :V 甲醇 =10:1;

[0114] After the reaction is completed, the solvent is first removed by vacuum distillation, then dissolved with n-butanol (15 mL), washed with saturated sodium chloride solution (15 mL) 4-5 times, and the n-butanol phase is dried over anhydrous sodium sulfate. Filter, remove the solvent by vacuum distillation, and then separate the product by column chromatography to obtain a white solid compound AA-RA-1 (0.0843 g, 40.1%);

[0115] The H NMR spectrum of compound AA-RA-1 is shown in Figure 1 As shown, the structural characterization data of compound AA-RA-1 are as follows:

[0116] 1H NMR (600 MHz, CD3OD) δ 5.42-5.36 (m, 2H), 3.69 (td, J = 11.4, 4.6Hz, 1H), 3.61 (dd, J = 11.4, 4.6 Hz, 1H), 3.53 (d, J = 11.1 Hz, 1H), 3.50 (d,J = 11.1 Hz, 1H), 3.36 (d, J = 9.6 Hz, 1H), 3.30 (d, J = 10.9 Hz, 1H), 3.26(d, J = 10.7 Hz, 3H), 3.15 - 3.04 (m, 2H), 2.68 (td, J = 13.5, 4.6 Hz, 1H),2.41 (s, 1H), 2.15 - 2.09 (m, 1H), 2.09 - 1.93 (m, 6H), 1.81 - 1.73 (m, 3H),1.73 - 1.59 (m, 11H), 1.52 (dd, J = 15.5, 11.1 Hz, 4H), 1.46 (dd, J = 15.6,6.9 Hz, 4H), 1.35 (s, 3H), 1.29 (td, J = 9.3, 8.7, 4.7 Hz, 4H), 1.22 (s, 3H),1.19 (t, J = 3.6 Hz, 2H), 1.14 (s, 3H), 1.05 (s, 3H), 0.98 (d, J = 2.9 Hz,6H), 0.94 - 0.90 (m, 6H), 0.79 (s, 3H), 0.73 (s, 3H), 0.71 - 0.68 (m, 6H). 13CNMR (151 MHz, CD3OD) δ 181.49, 180.92, 140.03, 139.98, 129.74, 127.05, 78.09,73.95, 73.85, 69.63, 67.41, 66.22, 54.83, 54.07, 49.57, 48.82, 48.80, 48.77,48.48, 48.07, 47.94, 44.12, 43.38, 43.27, 43.05, 42.63, 41.19, 41.16, 41.05,40.90, 40.83, 40.71, 7, 17.84, 17.83, 17.78, 16.66, 16.39, 14.05, 12.86.

[0117] Example 2

[0118] Synthesis of compound AA-RA-2.

[0119] Example 2 adopts the same preparation process as Example 1, and the only difference from Example 1 is that 1,2-ethylenediamine in step (3) of Example 1 is replaced by 1,4-butylenediamine; the yield of compound AA-RA-2 is 32%.

[0120] The H NMR spectrum of compound AA-RA-2 is shown in Figure 2 As shown, the structural characterization data of compound AA-RA-2 are as follows:

[0121] 1<h2 style=";text-align:left;direction:ltr">H NMR (600 MHz, CD3OD) δ 7.25 - 7.15 (m, 2H), 5.38-5.33 (m, 2H), 3.71(td, J = 11.4, 9.5, 4.5 Hz, 1H), 3.62 (dd, J = 11.6, 4.6 Hz, 1H), 3.54 (d, J = 11.0 Hz, 1H), 3.52 (d, J = 11.0 Hz, 1H), 3.37 (d, J = 9.6 Hz, 1H), 3.31 (d, J = 8.7 Hz, 1H), 3.27 (d, J = 11.0 Hz, 1H), 3.17 (dt, J = 12.8, 6.3 Hz, 2H),3.09 (q, J = 7.0, 6.3 Hz, 2H), 2.69 (td, J = 13.5, 4.5 Hz, 1H), 2.49 (s, 1H),2.16 (d, J = 11.0 Hz, 1H), 2.11 - 2.03 (m, 2H), 2.01 (d, J = 3.5 Hz, 2H),2.01 - 1.92 (m, 3H), 1.82 (dd, J = 13.8, 4.5 Hz, 1H), 1.79 - 1.60 (m, 13H),1.56 - 1.49 (m, 5H), 1.48 (s, 5H), 1.47 - 1.44 (m, 2H), 1.36 (s, 3H), 1.32 -1.25 (m, 4H), 1.22 (s, 3H), 1.15 (s, 3H), 1.06 (s, 3H), 0.99 (s, 7H), 0.93(dd, J = 8.4, 6.6 Hz, 6H), 0.82 (s, 3H), 0.76 (s, 3H), 0.72 (d, J = 6.2 Hz, 6H).<h2 style=";text-align:left;direction:ltr"> 13C NMR (151 MHz, CD3OD) δ 180.76, 180.20, 140.31, 140.28, 129.50, 126.85,78.16, 74.03, 73.88, 69.65, 67.51, 66.29, 54.81, 54.17, 49.57, 48.81, 48.78,48.57, 48.51, 48.12, 47.97, 44.12, 43.46, 43.27, 43.02, 42.68, 41.15, 40.91,40.83, 40.44, 40.38, 40.33, 14.73, 24.55, 24.11, 21.62, 19.32, 19.09, 18.14, 17.84, 17.77, 16.67, 16.38,14.00, 12.80.

[0122] Example 3

[0123] Synthesis of compound AA-UA-1.

[0124] Example 3 adopts the same preparation process as Example 1, and the only difference from Example 1 is that RA in step (1) of Example 1 is replaced by UA; the yield of compound AA-UA-1 is 27%.

[0125] The H NMR spectrum of compound AA-UA-1 is as follows Figure 3 As shown, the structural characterization data of compound AA-UA-1 are as follows:

[0126] 1 H NMR (400 MHz, DMSO- d6) δ 7.26 (br, 1H), 7.07 (br, 1H), 5.25 - 5.17(m, 2H), 4.43 - 4.37 (m, 2H), 4.25 - 4.13 (m, 3H), 3.52 - 3.38 (m, 3H), 3.33- 3.28 (m, 2H), 3.17 (d, J = 9.7 Hz, 1H), 3.09 - 2.89 (m, 6H), 2.14 (t, J =11.3 Hz, 2H), 1.97 - 1.65 (m, 10H), 1.64 - 1.50 (m, 7H), 1.48 (s, 3H), 1.47 -1.29 (m, 15H), 1.18 (dq, J = 25.4, 12.7, 11.0 Hz, 10H), 1.03 (s, 6H), 0.93 -0.90 (m, 9H), 0.87 (s, 6H), 0.84 - 0.79 (m, 6H), 0.66 (d, J = 5.2 Hz, 6H),0.58 - 0.48 (m, 6H). 13 C NMR (101 MHz, DMSO- d 6) δ 176.59, 176.04, 138.62,138.45, 124.58, 75.53, 70.30, 67.43, 64.47, 63.90, 51.95, 46.97, 46.50,46.37, 45.97, 42.48, 41.83, 41.70, 41.64, 41.58, 38.99, 38.48, 38.09, 37.27,37.10, 36.20, 32.23, 30.46, 27.36, 26.58, 26.38, 23.56, 23.36, 23.01, 21.15,17.43, 17.21, 17.16, 16.91, 16.87, 15.63, 15.58, 13.77, 12.68.

[0127] Example 4

[0128] Synthesis of compound AA-UA-2.

[0129] Example 4 adopts the same preparation process as Example 1, and the only difference from Example 1 is that RA in step (1) of Example 1 is replaced by UA, and 1,2-ethylenediamine in step (3) is replaced by 1,4-butylenediamine, to obtain compound AA-UA-2 with a yield of 30%.

[0130] The H NMR spectrum of compound AA-UA-2 is as follows Figure 4 As shown, the structural characterization data of compound AA-UA-2 are as follows:

[0131] 1 H NMR (400 MHz, DMSO- d 6) δ 7.28 - 7.23 (m, 1H), 7.10 - 7.03 (m, 1H), 5.30 - 5.17 (m, 2H), 4.44 - 4.37 (m, 2H), 4.25 - 4.19 (m, 1H), 4.19 - 4.13(m, 2H), 3.52 - 3.39 (m, 3H), 3.34 - 3.27 (m, 1H), 3.20 - 3.13 (m, 1H), 3.10- 2.98 (m, 4H), 2.98 - 2.90 (m, 2H), 2.19 - 2.08 (m, 2H), 1.98 - 1.84 (m,5H), 1.84 - 1.73 (m, 3H), 1.64 - 1.51 (m, 6H), 1.51 - 1.43 (m, 6H), 1.38 (d,J = 11.6 Hz, 7H), 1.35 - 1.29 (m, 4H), 1.27 - 1.05 (m, 11H), 1.02 (s, 5H), 0.91 (d, J = 4.6 Hz, 11H), 0.88 - 0.79 (m, 11H), 0.72 - 0.61 (m, 7H), 0.55 -0.49 (m, 6H). 13 C NMR (151 MHz, DMSO- d6) δ 181.49, 180.92, 140.03, 139.98,129.74, 127.05, 78.09, 73.95, 73.85, 69.63, 67.41, 66.22, 54.83, 54.07,49.57, 48.82, 48.80, 48.77, 48.48, 48.07, 47.94, 44.12, 43.38, 43.27, 43.05,42.63, 41.19, 41.16, 41.05, 40.90, 40.83, 40.71, 40.36, 39.92, 17.84, 17.83, 17.78,16.66, 16.39, 14.05, 12.86.

[0132] Example 5

[0133] Synthesis of compound RA-UA-1.

[0134] Example 5 adopts the same preparation process as Example 1, and the only difference from Example 1 is that AA in step (2) of Example 1 is replaced by UA; the yield of compound RA-UA-1 is 35%.

[0135] The H NMR spectrum of compound RA-UA-1 is shown in Figure 5 As shown, the structural characterization data of compound RA-UA-1 are as follows:

[0136] 1H NMR (600 MHz, CDCl3) δ 5.39 (t, J = 3.8 Hz, 1H), 5.30 (t, J = 3.6Hz, 1H), 3.71 (d, J = 10.3 Hz, 2H), 3.68 - 3.61 (m, 2H), 3.41 (dd, J = 10.4,3.0 Hz, 2H), 3.37 - 3.23 (m, 1H), 3.14 - 2.94 (m, 2H), 2.59 (td, J = 13.7,4.3 Hz, 1H), 2.42 (s, 1H), 2.05 - 1.89 (m, 5H), 1.89 - 1.81 (m, 2H), 1.75 -1.58 (m, 19H), 1.58 - 1.48 (m, 6H), 1.48 - 1.34 (m, 16H), 1.25 (d, J = 6.4Hz, 9H), 1.22 (s, 3H), 1.08 (s, 3H), 1.06 - 0.98 (m, 5H), 0.97 - 0.92 (m,12H), 0.89 (d, J = 2.7 Hz, 6H), 0.86 (d, J = 6.4 Hz, 6H), 0.76 (s, 3H), 0.71(s, 3H). 13 C NMR (151 MHz, CDCl3) δ 178.47, 178.25, 140.03, 138.98, 129.20,125.65, 77.16, 77.06, 73.64, 72.35, 72.25, 53.91, 53.59, 49.85, 47.83, 47.61,47.44, 47.28, 46.02, 42.64, 41.89, 41.61, 41.33, 40.09, 39.91, 39.66, 39.22,39.17, 39.07, 38.45, 38.26, 37.40, 36.97, 32.64, 31.03, 29.84, 28.11, 27.97,27.71, 27.00, 26.88, 26.74, 26.34, 26.12, 24.98, 24.47, 23.88, 23.54, 23.42,21.38, 18.73, 18.57, 17.39, 17.14, 17.08, 16.34, 16.05, 15.78, 11.63, 11.57,8.76。

[0137] Example 6

[0138] Synthesis of compound RA-UA-2.

[0139] Example 5 adopts the same preparation process as Example 1, and the only difference from Example 1 is that AA in step (2) of Example 1 is replaced by UA, and 1,2-ethylenediamine in step (3) is replaced by 1,4-butylenediamine; the yield of compound RA-UA-2 is 32%.

[0140] The H NMR spectrum of compound RA-UA-2 is shown in Figure 6 As shown, the structural characterization data of compound RA-UA-2 are as follows:

[0141] 1 H NMR (600 MHz, CD3OD) δ 5.42 - 5.36 (m, 2H), 3.62 (dd, J = 11.5, 4.8Hz, 2H), 3.53 (d, J = 10.9 Hz, 2H), 3.26 - 3.23 (m, 1H), 3.15 - 3.06 (m, 2H),3.00 (s, 1H), 2.86 (s, 1H), 2.69 (td, J = 13.5, 5.2 Hz, 1H), 2.42 (s, 1H),2.12 (d, J = 11.0 Hz, 1H), 2.10 - 2.03 (m, 2H), 2.03 - 1.95 (m, 3H), 1.77 (t,J = 12.3 Hz, 2H), 1.72 (d, J = 15.7 Hz, 2H), 1.69 (s, 2H), 1.68 - 1.58 (m,10H), 1.57 - 1.51 (m, 3H), 1.50 (s, 1H), 1.49 - 1.43 (m, 4H), 1.36 (d, J =14.0 Hz, 6H), 1.29 (s, 2H), 1.25 (d, J = 14.3 Hz, 2H), 1.22 (s, 3H), 1.20 -1.15 (m, 3H), 1.14 (s, 3H), 1.08 - 0.97 (m, 14H), 0.93 (t, J = 7.7 Hz, 7H),0.79 (s, 3H), 0.76 - 0.68 (m, 9H). 13C NMR (151 MHz, CD3OD) δ 181.43, 180.85,140.03, 139.86, 129.69, 127.19, 74.01, 73.81, 67.53, 67.37, 54.80, 54.08,48.82, 48.79, 48.78, 48.46, 47.94, 44.02, 43.30, 43.25, 43.03, 42.61, 41.17,41.14, 41.03, 40.84, 40.71, 40.33, 39.91, 39.59, 39.45, 38.89, 17.84, 17.98, 17.86, 17.73, 17.91, 17.87, 17.97, 17.89, 18.91, 18.83, 18.97, 18.88, 18.90, 18.97, 18.84, 18.86, 18.91, 18.87, 18.93, 18.88, 18.88, 18.91, 18.83, 18.97, 18.84, 18.91, 18.83, 18.97, 18.84, 18.85,

[0142] Example 7

[0143] The anti-inflammatory activities of the compounds AA-RA-1, AA-RA-2, AA-UA-1, AA-UA-2, RA-UA-1 and RA-UA-2 prepared above will be verified below.

[0144] Establishment of LPS-induced inflammation model in mouse macrophage RAW264.7 cells

[0145] Mouse macrophage RAW264.7 cell line was cultured in high-glucose DMEM medium containing 10% fetal bovine serum and 1% penicillin-streptomycin, placed in a 37°C, 5% CO2 and saturated humidity incubator for adherent growth, observed once a day under an inverted microscope, and the culture medium was changed every 2 days as the cell source for the experiment. When the cells in the culture flask grew to 85-95% confluence, the cells were passaged and transferred to a new sterile culture flask at a ratio of 1:3 for culture.

[0146] Accurately weigh the above compounds, convert them according to their molecular weight and purity, and prepare them into 20mM stock solutions with DMSO, and store them at -20℃ for later use. In this experiment, dexamethasone (DEX) was used as a control drug. The dosage design was based on the preliminary experimental results of DEX and the above compounds, and the final concentration of the test compound was determined to be 20 μM. First, take the mother solution of 20 mM and dilute it 1000 times with complete culture medium to obtain the compound working solution (containing 0.1% DMSO).

[0147] Take RAW264.7 cells in the exponential growth phase, and when the cells grow to 85-95% confluence, digest and collect the cells using the conventional subculture method, count the cells, and adjust the cell density to 3×10 5 The cells were inoculated into 96-well cell culture plates at 100 μL / well and incubated at 37°C with 5% CO2.

[0148] After the cells were seeded and attached for 12 h, the supernatant was discarded and replaced with 90 μL / well of 20 μM working solution of each compound. Three replicate wells were set up, and a normal control group and a model control group were also set up. After adding the drug, the culture was continued for 1 h.

[0149] Accurately weigh LPS and prepare a stock solution with a concentration of 2 mg / mL using sterile PBS. After aliquoting, store it at -80℃ for later use. According to the literature and the preliminary test of this research group, the final concentration of LPS is determined to be 1 μg / mL. During the experiment, take a tube of stock solution to thaw and dilute it 200 times with complete culture medium to a concentration of 10 μg / mL LPS working solution. One hour after adding the drug, remove the culture plate, add 10 μL of LPS working solution to each well, and continue to culture in the incubator for 24 hours. After culturing for 24 hours, centrifuge the 96-well plate at 4℃, 2500 r / min for 5 minutes, take an appropriate amount of supernatant, and samples that are not tested in time should be stored at -20℃.

[0150] The recommended concentrations of the TNF-α ELISA kit standard curve are 250 pg / mL, 125 pg / mL, 62.5 pg / mL, 31.25 pg / mL, 15.6 pg / mL, 7.81 pg / mL, 3.9 pg / mL, and 0 pg / mL. According to the results of the preliminary test, the TNF-α concentration in the cell supernatant was much higher than the maximum concentration of the standard. Finally, the optimal dilution multiple of the normal control group sample was determined to be 50 times, and the optimal dilution multiple of the model control group and each drug group was 250 times. The samples were diluted with the sample diluent in the kit.

[0151] The detection steps are as follows:

[0152] 1. Sample addition: Add 100 μL of each gradient standard and appropriately diluted sample to the wells of the ELISA plate pre-coated with anti-TNF-α antibody provided in the kit, and add 100 μL of sample diluent to the blank wells. Apply the film and incubate at 37°C for 90 min;

[0153] 2. Wash the plate twice: remove the film, absorb or shake off the liquid in the ELISA plate, and tap it on clean absorbent paper 2-3 times. Add 350 μL of washing buffer to each well, do not soak, discard the liquid in the well, and tap it on absorbent paper 2-3 times. Repeat this washing step 2 times;

[0154] 3. Add biotin-antibody working solution: Add 100 μL of biotin-antibody working solution to each well. Apply the film and incubate at 37°C for 60 min.

[0155] 4. Wash the plate 3 times: remove the film, absorb or shake off the liquid in the ELISA plate, and tap it on clean absorbent paper 2-3 times. Add 350 μL of washing buffer to each well, soak for 1 min, discard the liquid in the well, and tap it on absorbent paper 2-3 times. Repeat the washing step 3 times;

[0156] 5. Add HRP-streptavidin biotin complex (SABC): Add 100 μL SABC working solution to each well. Apply the film and incubate at 37°C for 30 min.

[0157] 6. Wash the plate 5 times: remove the film and wash the plate 5 times with washing buffer, referring to step 4;

[0158] 7. Add TMB colorimetric substrate: Add 90 μL TMB colorimetric substrate to each well, apply the film, and incubate at 37°C in the dark for 10 - 20 min;

[0159] 8. Add reaction stop solution: After color development, the liquid in the wells cannot be discarded. Add 50 μL of reaction stop solution to each well;

[0160] 9. Measurement of OD value: Immediately read the OD450 value at 450 nm using an enzyme reader;

[0161] The TNF-α concentration in the cell supernatant was calculated based on the absorbance value of the sample and the standard curve of the kit, and the data processing software GraphPad Prism 8 was used to draw the graph.

[0162] Experimental results: The effects of the positive reference drug DEX and the test compound at a concentration of 20 μM on LPS-induced TNF-α secretion in mouse macrophage RAW264.7 cells were shown in Figure 7 .

[0163] Among them, the above-mentioned test compounds all had a significant inhibitory effect on the secretion of TNF-α, and the inhibition rates of DEX, AA-RA-1, RA-UA-1, AA-UA-1, AA-RA-2, RA-UA-2, and AA-UA-2 were 18.3%, 42.1%, 27.2%, 18.7%, 14.2%, 34.4%, and 42.5%, respectively.

[0164] Combination Figure 7 The test results show that DEX and the tested compounds have comparable effects on inhibiting the secretion of TNF-α; among them, compounds AA-RA-1, RA-UA-1, RA-UA-2, and AA-UA-2 have more significant inhibitory effects on the secretion of TNF-α. The above results show that the twin-drug pentacyclic triterpene derivative can effectively inhibit the secretion of TNF-α.

[0165] In summary, the pentacyclic triterpene derivative provided in this embodiment combines two compounds in the form of an amide bond, which not only reduces the acidity of the lead compound, but also significantly improves the antioxidant activity of the compound through synergistic effects, thereby effectively inhibiting the release of inflammatory mediators and oxidative stress response during inflammation, thereby improving the anti-inflammatory activity of the derivative, indicating that the pentacyclic triterpene derivative has good application prospects in the preparation of anti-inflammatory drugs.

[0166] The technical solutions provided in the embodiments of the present application are introduced in detail above. Specific examples are used herein to illustrate the principles and implementation methods of the embodiments of the present application. The description of the above embodiments is only applicable to help understand the principles of the embodiments of the present application. At the same time, for those skilled in the art, according to the embodiments of the present application, there will be changes in the specific implementation methods and application scopes. In summary, the contents of this specification should not be understood as limiting the present application.

Claims

1. A pentacyclic triterpene derivative, characterized in that: The pentacyclic triterpene derivative has a compound having a structure shown in Formula I or a pharmaceutically acceptable salt thereof: , Wherein, R1, R2, R3, and R4 are each independently selected from hydrogen or hydroxyl, and R1, R2, R3, and R4 are not hydrogen or hydroxyl at the same time; n is an integer of 2 to 4.

2. The pentacyclic triterpene derivative according to claim 1, characterized in that n is 2 or 4.

3. The pentacyclic triterpene derivative according to claim 1, characterized in that The pentacyclic triterpene derivative is selected from at least one of the following compounds or pharmaceutically acceptable salts thereof: 、 、 、 、 、 。 4. Use of the pentacyclic triterpene derivative according to claim 1 in the preparation of a medicament for preventing, alleviating or treating inflammation.

5. The use according to claim 4, characterized in that The drug is used to inhibit the release of inflammatory factors.

Citation Information

Patent Citations

  • Triterpene derivative and preparation method and application

    CN103127135A

  • Novel medical application of ethane-1,2-double ovate leaf holly bark acid ester

    CN107188923A

  • Fat accumulation- or metabolism-ameliorating agent, Anti-TNF-alpha agent and new triterpene compound

    JP2010095459A